Compare
Compare archived captures
This view highlights text differences between two archived captures. It does not interpret meaning or provide guidance.
Descriptive changes only
This comparison highlights text changes between archived captures. It does not interpret the change or provide medical advice. For up-to-date recommendations, always consult the official source website.
Need to cite this comparison? See /cite.
Earlier capture
Applications and Submissions - Biologics, Radiopharmaceuticals and Genetic Therapies - Health Canada - Canada.ca
Apr 18, 2025
legacy-hc-2025-04-21
ID 249959
Later capture
Applications and Submissions - Biologics, Radiopharmaceuticals and Genetic Therapies - Health Canada - Canada.ca
Jan 2, 2026
hc-20260101
ID 428836
updated1 sections changed
1 sections changed0 added0 removed+1 / -2 linesChange ratio: 27%
--- +++ @@ -2,5 +2,4 @@ All drugs that are marketed in Canada are subject to the Food and Drugs Act and Regulations. The Biologics and Genetic Therapies Directorate is responsible for the review and approval of all types of drug submissions for Biological (Schedule D) and Radiopharmaceutical (Schedule C) drug products, including, but not limited to New Drug Submissions (NDSs) and Clinical Trial Applications (CTAs). For the regulatory requirements specific to Radiopharmaceutical (Schedule C to the Act) or Biological (Schedule D to the Act) drugs, please refer to Divisions 3 and 4, respectively, of Part C of the Regulations. For general regulatory requirements concerning all drugs, including Good Manufacturing Practices, please refer to Divisions 1, 1a, 2, 5 and 8 of Part C of the Regulations. The guidance documents, policies, forms, and templates provided will aid in the preparation of drug submissions. Page details-Date modified:-2007-10-31+2017-05-04